Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20370621rdf:typepubmed:Citationlld:pubmed
pubmed-article:20370621lifeskim:mentionsumls-concept:C1159339lld:lifeskim
pubmed-article:20370621lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:20370621lifeskim:mentionsumls-concept:C0280118lld:lifeskim
pubmed-article:20370621lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:20370621lifeskim:mentionsumls-concept:C1829683lld:lifeskim
pubmed-article:20370621lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:20370621lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:20370621pubmed:issue1lld:pubmed
pubmed-article:20370621pubmed:dateCreated2010-4-7lld:pubmed
pubmed-article:20370621pubmed:abstractTextAs the breadth and number of bacterial pathogens exhibiting antibiotic resistance is rapidly increasing, our ability to treat new and re-emerging infectious diseases is being threatened. Therefore, the development of new therapeutic strategies, including drugs acting on new targets, is required. In this review, the feasibility of gram-negative bacterial secretion systems for the development of anti-virulence agents and possible arenas for their utility in therapeutic intervention of gram-negative bacterial infections such as gastroenteritis, nosocomial infections, and venereal diseases are discussed.lld:pubmed
pubmed-article:20370621pubmed:languageenglld:pubmed
pubmed-article:20370621pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20370621pubmed:citationSubsetIMlld:pubmed
pubmed-article:20370621pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20370621pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20370621pubmed:statusMEDLINElld:pubmed
pubmed-article:20370621pubmed:issn1040-8401lld:pubmed
pubmed-article:20370621pubmed:authorpubmed-author:MillerSamuel...lld:pubmed
pubmed-article:20370621pubmed:authorpubmed-author:FeliseHeather...lld:pubmed
pubmed-article:20370621pubmed:issnTypePrintlld:pubmed
pubmed-article:20370621pubmed:volume30lld:pubmed
pubmed-article:20370621pubmed:ownerNLMlld:pubmed
pubmed-article:20370621pubmed:authorsCompleteYlld:pubmed
pubmed-article:20370621pubmed:pagination69-77lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:meshHeadingpubmed-meshheading:20370621...lld:pubmed
pubmed-article:20370621pubmed:year2010lld:pubmed
pubmed-article:20370621pubmed:articleTitleProspects for the development and use of gram-negative bacterial virulence protein secretion inhibitors for prophylaxis and treatment of infectious diseases.lld:pubmed
pubmed-article:20370621pubmed:affiliationDepartment of Microbiology, University of Washington, Seattle, Washington 98195, USA. hrb@u.washington.edu.lld:pubmed
pubmed-article:20370621pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20370621pubmed:publicationTypeReviewlld:pubmed